

Manish K Aghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3807812/publications.pdf>

Version: 2024-02-01

230
papers

16,331
citations

25014

57
h-index

18115

120
g-index

238
all docs

238
docs citations

238
times ranked

27479
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. <i>Cancer Cell</i> , 2012, 22, 21-35.	7.7	495
3	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. <i>Genome Biology</i> , 2017, 18, 234.	3.8	448
4	LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION. <i>Neurosurgery</i> , 2009, 64, 56-60.	0.6	418
5	Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma. <i>Cancer Research</i> , 2012, 72, 1773-1783.	0.4	395
6	Impact of extent of resection for recurrent glioblastoma on overall survival. <i>Journal of Neurosurgery</i> , 2012, 117, 1032-1038.	0.9	370
7	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
8	Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. <i>Cancer Research</i> , 2009, 69, 3472-3481.	0.4	303
9	Oncolytic viral therapies – the clinical experience. <i>Oncogene</i> , 2005, 24, 7802-7816.	2.6	269
10	The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. <i>Cancer Discovery</i> , 2019, 9, 1708-1719.	7.7	205
11	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. <i>Neurosurgery</i> , 2012, 70, 234-244.	0.6	204
12	Prodrug activation enzymes in cancer gene therapy. <i>Journal of Gene Medicine</i> , 2000, 2, 148-164.	1.4	191
13	Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. <i>Neuro-Oncology</i> , 2014, 16, 274-279.	0.6	188
14	Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. <i>Neuro-Oncology</i> , 2012, 14, 942-954.	0.6	183
15	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 33, 874-889.e7.	7.7	180
16	Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 1773-1783.	3.2	177
17	Biology of Angiogenesis and Invasion in Glioma. <i>Neurotherapeutics</i> , 2009, 6, 447-457.	2.1	174
18	Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy. <i>Cancer Research</i> , 2012, 72, 4294-4299.	0.4	170

#	ARTICLE	IF	CITATIONS
19	Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes. <i>Cancer Research</i> , 2006, 66, 9054-9064.	0.4	165
20	Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. <i>Journal of Neurosurgery</i> , 2017, 126, 191-200.	0.9	148
21	The role of surgery in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 503-530.	1.4	147
22	Î²1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma. <i>Cancer Research</i> , 2013, 73, 3145-3154.	0.4	140
23	Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication. <i>Journal of the National Cancer Institute</i> , 2006, 98, 38-50.	3.0	135
24	New advances that enable identification of glioblastoma recurrence. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 648-657.	12.5	134
25	Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 48-54.	0.8	129
26	Convection-enhanced delivery for the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, ii3-ii8.	0.6	124
27	Rathke's cleft cysts: review of natural history and surgical outcomes. <i>Journal of Neuro-Oncology</i> , 2014, 117, 197-203.	1.4	104
28	Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 8600-8605.	3.2	103
29	Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. <i>Nature Reviews Materials</i> , 2019, 4, 651-668.	23.3	103
30	Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 2930-2942.	3.2	102
31	The Role of Cancer-Associated Fibroblasts in Tumor Progression. <i>Cancers</i> , 2021, 13, 1399.	1.7	98
32	Impact of bevacizumab chemotherapy on craniotomy wound healing. <i>Journal of Neurosurgery</i> , 2011, 114, 1609-1616.	0.9	93
33	Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas. <i>Molecular Systems Biology</i> , 2016, 12, 889.	3.2	91
34	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
35	Î²1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond. <i>Cancer Research</i> , 2014, 74, 3-7.	0.4	84
36	Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transphenoidal approach. <i>Neurosurgical Focus</i> , 2018, 44, E9.	1.0	81

#	ARTICLE	IF	CITATIONS
37	Dopamine agonist-resistant prolactinomas. <i>Journal of Neurosurgery</i> , 2011, 114, 1369-1379.	0.9	80
38	HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth. <i>Cell Reports</i> , 2015, 10, 891-899.	2.9	79
39	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E533-E535.	0.6	77
40	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1490-1496.	0.8	76
41	Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. <i>Journal of Neuro-Oncology</i> , 2020, 147, 525-529.	1.4	76
42	Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations. <i>Journal of Neurosurgery</i> , 2013, 119, 1478-1483.	0.9	75
43	Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis. <i>Journal of Neurosurgery</i> , 2016, 124, 589-595.	0.9	75
44	Contribution of Bone Marrow-Derived Cells to Blood Vessels in Ischemic Tissues and Tumors. <i>Molecular Therapy</i> , 2005, 12, 994-1005.	3.7	74
45	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. <i>Neuro-Oncology</i> , 2010, 12, 822-833.	0.6	74
46	Bone involvement predicts poor outcome in atypical meningioma. <i>Journal of Neurosurgery</i> , 2009, 111, 464-471.	0.9	73
47	A Comprehensive Long-term Retrospective Analysis of Silent Corticotrophic Adenomas vs Hormone-Negative Adenomas. <i>Neurosurgery</i> , 2013, 73, 8-18.	0.6	73
48	Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. <i>Neurosurgery</i> , 2015, 76, 179-186.	0.6	72
49	Sinonasal morbidity following endoscopic endonasal skull base surgery. <i>Clinical Neurology and Neurosurgery</i> , 2015, 130, 162-167.	0.6	71
50	Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. <i>Journal of Neuro-Oncology</i> , 2009, 92, 401-415.	1.4	68
51	Endoscopic surgery for tuberculoma sellae meningiomas: a systematic review and meta-analysis. <i>Neurosurgical Review</i> , 2013, 36, 349-359.	1.2	68
52	Nationwide shift from microscopic to endoscopic transsphenoidal pituitary surgery. <i>Pituitary</i> , 2016, 19, 248-250.	1.6	68
53	Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. <i>Seminars in Oncology</i> , 2019, 46, 284-290.	0.8	68
54	Suprasellar Rathke Cleft Cysts. <i>Neurosurgery</i> , 2011, 69, 1058-1069.	0.6	65

#	ARTICLE	IF	CITATIONS
55	Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. <i>Molecular Therapy</i> , 2009, 17, 51-56.	3.7	64
56	Angiogenic Response Caused by Oncolytic Herpes Simplex Virus-Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide. <i>Cancer Research</i> , 2007, 67, 440-444.	0.4	62
57	Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment. <i>Neurosurgery</i> , 2012, 70, 361-370.	0.6	60
58	Hypophysitis: a single-center case series. <i>Pituitary</i> , 2015, 18, 630-641.	1.6	60
59	Pituicytomas and spindle cell oncocytomas: modern case series from the University of California, San Francisco. <i>Pituitary</i> , 2015, 18, 150-158.	1.6	60
60	Cross-activating c-Met/ β 1 integrin complex drives metastasis and invasive resistance in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8685-E8694.	3.3	60
61	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E539-E540.	0.6	59
62	Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. <i>Autophagy</i> , 2012, 8, 979-981.	4.3	57
63	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	3.9	57
64	Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations. <i>Journal of Neurosurgery</i> , 2014, 121, 67-74.	0.9	56
65	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. <i>Nature Communications</i> , 2020, 11, 4803.	5.8	56
66	Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. <i>Journal of Neurosurgery</i> , 2018, 130, 1-8.	0.9	54
67	The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 281-286.	0.8	51
68	Convection-enhanced drug delivery for glioblastoma: a review. <i>Journal of Neuro-Oncology</i> , 2021, 151, 415-427.	1.4	50
69	GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. <i>JCI Insight</i> , 2017, 2, e88815.	2.3	49
70	Breast Adenocarcinoma Metastatic to Epidural Cervical Spine Meningioma: Case Report and Review of the Literature. <i>Journal of Neuro-Oncology</i> , 2005, 75, 149-155.	1.4	48
71	Endoscopic skull base and transoral surgery during COVID-19 pandemic: Minimizing droplet spread with negative-pressure otolaryngology viral isolation drape. <i>Head and Neck</i> , 2020, 42, 1577-1582.	0.9	47
72	Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab100.	0.4	47

#	ARTICLE	IF	CITATIONS
73	Excess mortality for patients with residual disease following resection of pituitary adenomas. <i>Pituitary</i> , 2011, 14, 276-283.	1.6	46
74	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Techniques and Technologies for the Management of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E536-E538.	0.6	44
75	Safety and outcomes of resection of butterfly glioblastoma. <i>Neurosurgical Focus</i> , 2018, 44, E4.	1.0	43
76	The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007â€“2017. <i>World Neurosurgery</i> , 2020, 137, e584-e596.	0.7	42
77	Phase Ib Trial of Oncolytic Herpes Virus G207 Shows Safety of Multiple Injections and Documents Viral Replication. <i>Molecular Therapy</i> , 2009, 17, 8-9.	3.7	41
78	Systemic therapy for brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 44-50.	2.0	41
79	Meningioma metastases: incidence and proposed screening paradigm. <i>Journal of Neurosurgery</i> , 2020, 132, 1447-1455.	0.9	41
80	Management of recurrent and refractory Cushing disease. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 560-568.	2.9	40
81	A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. <i>Journal of Neurosurgery</i> , 2011, 115, 754-759.	0.9	40
82	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E527-E529.	0.6	40
83	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, 521-523.	0.6	38
84	Tumor treating fields: a new approach to glioblastoma therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 447-453.	1.4	38
85	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020, 22, 1568-1579.	0.6	38
86	Viral Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 167-179.	1.0	36
87	Neuropilin-1 modulates TGFÎ² signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. <i>PLoS ONE</i> , 2017, 12, e0185065.	1.1	35
88	Disparities in health care determine prognosis in newly diagnosed glioblastoma. <i>Neurosurgical Focus</i> , 2018, 44, E16.	1.0	35
89	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020, 8, 151.	2.4	35
90	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.4	35

#	ARTICLE	IF	CITATIONS
91	Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance. <i>Cancer Research</i> , 2020, 80, 1498-1511.	0.4	35
92	Heparin-induced Thrombocytopenia Type II in Subarachnoid Hemorrhage Patients: Incidence and Complications. <i>Neurosurgery</i> , 2005, 57, 243-248.	0.6	34
93	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E541-E543.	0.6	34
94	Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. <i>Journal of Neurosurgery</i> , 2012, 116, 283-289.	0.9	33
95	Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. <i>Journal of Neurosurgery</i> , 2016, 126, 1749-1755.	0.9	33
96	Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. <i>Neurosurgery</i> , 2017, 80, 129-139.	0.6	33
97	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	0.6	33
98	WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index. <i>Frontiers in Oncology</i> , 2020, 10, 1522.	1.3	33
99	Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. <i>Oncotarget</i> , 2019, 10, 2212-2223.	0.8	33
100	Nuclear Localization of the Mitochondrial Factor HIGD1A during Metabolic Stress. <i>PLoS ONE</i> , 2013, 8, e62758.	1.1	32
101	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pretreatment Ophthalmology Evaluation in Patients With Suspected Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E530-E532.	0.6	32
102	Cavernous and inferior petrosal sinus sampling and dynamic magnetic resonance imaging in the preoperative evaluation of Cushing's disease. <i>Journal of Neuro-Oncology</i> , 2014, 116, 593-600.	1.4	31
103	Metabolic Drivers of Invasion in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683276.	1.8	31
104	INCREASED PREVALENCE OF OBESITY AND OBESITY-RELATED POSTOPERATIVE COMPLICATIONS IN MALE PATIENTS WITH MENINGIOMAS. <i>Neurosurgery</i> , 2007, 61, 754-761.	0.6	30
105	Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. <i>Neurosurgery</i> , 2017, 81, 824-833.	0.6	30
106	Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. <i>Clinical Neurosurgery</i> , 2008, 55, 141-4.	0.2	30
107	Surgical outcomes in choroid plexus papillomas: an institutional experience. <i>Journal of Neuro-Oncology</i> , 2013, 113, 117-125.	1.4	29
108	Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications. <i>Neurosurgery</i> , 2018, 83, 1161-1172.	0.6	29

#	ARTICLE	IF	CITATIONS
109	Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. <i>Scientific Reports</i> , 2021, 11, 12162.	1.6	28
110	Incidence of headache as a presenting complaint in over 1000 patients with sellar lesions and factors predicting postoperative improvement. <i>Clinical Neurology and Neurosurgery</i> , 2015, 132, 16-20.	0.6	27
111	Ventriculoperitoneal Shunting for Glioblastoma: Risk Factors, Indications, and Efficacy. <i>Neurosurgery</i> , 2017, 80, 421-430.	0.6	27
112	Infected Rathke Cleft Cysts. <i>Neurosurgery</i> , 2010, 67, 762-769.	0.6	26
113	Autophagy as a mechanism for anti-angiogenic therapy resistance. <i>Seminars in Cancer Biology</i> , 2020, 66, 75-88.	4.3	26
114	Salvage therapy outcomes for atypical meningioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 425-433.	1.4	25
115	ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. <i>Genome Biology</i> , 2021, 22, 311.	3.8	25
116	Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 125-131.	0.4	24
117	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	3.2	24
118	Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 116-120.	0.6	22
119	Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin α 21 Blocking Antibody OS2966. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1127-1136.	1.9	22
120	Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma. <i>Neurosurgery</i> , 2018, 82, 64-75.	0.6	22
121	Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. <i>Neurosurgical Focus</i> , 2020, 48, E13.	1.0	22
122	Socioeconomic factors associated with pituitary apoplexy. <i>Journal of Neurosurgery</i> , 2013, 119, 1432-1436.	0.9	21
123	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1497-1502.	0.8	21
124	Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 635-639.	1.4	21
125	Functional brain mapping: overview of techniques and their application to neurosurgery. <i>Neurosurgical Review</i> , 2019, 42, 639-647.	1.2	21
126	Surgical Cavity Constriction and Local Progression Between Resection and Adjuvant Radiosurgery for Brain Metastases. <i>Cureus</i> , 2016, 8, e575.	0.2	21

#	ARTICLE	IF	CITATIONS
127	Rate and Time Course of Improvement in Endocrine Function After More Than 1000 Pituitary Operations. <i>Neurosurgery</i> , 2014, 61, 163-166.	0.6	20
128	Surgical resection of fourth ventricular ependymomas: case series and technical nuances. <i>Journal of Neuro-Oncology</i> , 2016, 130, 341-349.	1.4	20
129	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Preoperative Imaging Assessment of Patients With Suspected Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E524-E526.	0.6	20
130	Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy. <i>Frontiers in Surgery</i> , 2017, 4, 35.	0.6	20
131	Atypical pituitary adenoma: a clinicopathologic case series. <i>Journal of Neurosurgery</i> , 2018, 128, 1058-1065.	0.9	20
132	The immunology of low-grade gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E2.	1.0	20
133	Unilateral vestibular schwannoma with other neurofibromatosis Type 2-related tumors: clinical and molecular study of a unique phenotype. <i>Journal of Neurosurgery</i> , 2006, 104, 201-207.	0.9	19
134	Disseminated progression of glioblastoma after treatment with bevacizumab. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1795-1801.	0.6	19
135	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
136	Growth hormone and prolactin-secreting tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. <i>Journal of Neurosurgery</i> , 2019, 131, 147-153.	0.9	19
137	Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 17580.	1.6	19
138	Preventing Delays in First-Case Starts on the Neurosurgery Service: A Resident-Led Initiative at an Academic Institution. <i>Journal of Surgical Education</i> , 2016, 73, 291-295.	1.2	18
139	Incorporating Tumor-Associated Macrophages into Engineered Models of Glioma. <i>IScience</i> , 2020, 23, 101770.	1.9	18
140	Mechanisms of evasion to antiangiogenic therapy in glioblastoma. <i>Clinical Neurosurgery</i> , 2010, 57, 123-8.	0.2	18
141	Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 86-100.	3.3	17
142	Petrous Face Meningiomas: Classification, Clinical Syndromes, and Surgical Outcomes. <i>World Neurosurgery</i> , 2018, 114, e1266-e1274.	0.7	17
143	Hyperostosing sphenoid wing meningiomas: surgical outcomes and strategy for bone resection and multidisciplinary orbital reconstruction. <i>Journal of Neurosurgery</i> , 2021, 134, 711-720.	0.9	17
144	Viral vectors as therapeutic agents for glioblastoma. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 419-30.	2.8	17

#	ARTICLE	IF	CITATIONS
145	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. <i>Neurosurgery</i> , 2022, 90, 124-130.	0.6	17
146	Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 2017, 446, 81-90.	1.6	16
147	A cross-sectional study of neurosurgical department chairs in the United States. <i>Journal of Neurosurgery</i> , 2018, 129, 1342-1348.	0.9	16
148	Surgical Outcomes, Complications, and Management Strategies for Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 001-009.	0.4	16
149	Gangliogliomas of the optic pathway. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2244-2249.	0.8	15
150	Extended endoscopic endonasal approach for suprasellar Rathke's cleft cysts. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 779-785.	0.8	15
151	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. <i>Journal of Neuro-Oncology</i> , 2020, 148, 131-139.	1.4	15
152	Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review. <i>Cancer Investigation</i> , 2003, 21, 278-292.	0.6	14
153	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. <i>Academic Radiology</i> , 2016, 23, 1073-1082.	1.3	14
154	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	4.3	14
155	Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care. <i>Journal of Neurosurgery</i> , 2019, 131, 281-289.	0.9	13
156	Molecular Biology of Pituitary Adenomas. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 391-400.	0.8	13
157	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	1.3	13
158	Gene therapy for glioblastoma. <i>Neurosurgical Focus</i> , 2006, 20, E18.	1.0	13
159	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
160	Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. <i>Journal of Neuro-Oncology</i> , 2009, 93, 115-20.	1.4	12
161	Optimizing glioblastoma resection: intraoperative mapping and beyond. <i>CNS Oncology</i> , 2014, 3, 359-366.	1.2	12
162	Role of c-Met/ β 1 integrin complex in the metastatic cascade in breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	12

#	ARTICLE	IF	CITATIONS
163	Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. <i>Journal of Neuroradiology</i> , 2012, 39, 263-266.	0.6	11
164	Anti-angiogenic therapies in the management of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 37-37.	0.4	11
165	Identifying risk factors for postoperative diabetes insipidus in more than 2500 patients undergoing transsphenoidal surgery: a single-institution experience. <i>Journal of Neurosurgery</i> , 2022, 137, 647-657.	0.9	11
166	Tumors of the anterior skull base. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 425-438.	1.4	10
167	Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. <i>Neurosurgery</i> , 2019, 85, 793-800.	0.6	10
168	Atypical meningiomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 170, 233-244.	1.0	10
169	Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	0.6	10
170	Impact of platybasia and anatomic variance on surgical approaches to the craniovertebral junction. <i>Laryngoscope</i> , 2014, 124, 1760-1766.	1.1	9
171	A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. <i>Journal of Neurosurgery</i> , 2021, 134, 1386-1391.	0.9	9
172	A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 155-160.	0.8	8
173	Approach to the postoperative patient with Cushing's disease. <i>Pituitary</i> , 2015, 18, 232-237.	1.6	8
174	Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 25-33.	1.2	8
175	CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma. <i>Scientific Reports</i> , 2022, 12, 1464.	1.6	8
176	Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 53-61.	1.4	7
177	Patients cured of acromegaly do not experience improvement of their skull deformities. <i>Pituitary</i> , 2017, 20, 292-294.	1.6	7
178	Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. <i>World Neurosurgery</i> , 2021, 146, e755-e767.	0.7	7
179	Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. <i>Journal of Neuro-Oncology</i> , 2021, 152, 1-13.	1.4	7
180	Recent advances in the treatment of acromegaly. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 304-307.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Microarray Analysis in Glioblastomas. <i>Methods in Molecular Biology</i> , 2015, 1375, 195-206.	0.4	6
182	Shunt Treatment for Coccidioidomycosis-Related Hydrocephalus: A Single-Center Series. <i>World Neurosurgery</i> , 2020, 138, e883-e891.	0.7	6
183	Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. <i>Clinical Neurosurgery</i> , 2006, 53, 65-76.	0.2	6
184	Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match. <i>World Neurosurgery</i> , 2020, 138, 553-555.	0.7	5
185	Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma. <i>World Neurosurgery</i> , 2022, 161, e448-e463.	0.7	5
186	Determinants of initial bone graft volume loss in posterolateral lumbar fusion. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1193-1196.	0.8	4
187	Getting More Out of Radiation Therapy in Glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 4-6.	0.6	4
188	Adaptation to antiangiogenic therapy in neurological tumors. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3069-3082.	2.4	4
189	Letter to the Editor Regarding "Geographic Distribution of International Medical Graduate Residents in U.S. Neurosurgery Training Programs". <i>World Neurosurgery</i> , 2020, 138, 591.	0.7	4
190	Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series. <i>World Neurosurgery</i> , 2021, 151, e185-e191.	0.7	4
191	Geographic landscape of foreign medical graduates in US neurosurgery training programs from 2007 to 2017. <i>Clinical Neurology and Neurosurgery</i> , 2021, 209, 106891.	0.6	4
192	Intraoperative Conversion from Endoscopic to Open Transcortical Transventricular Removal of Colloid Cysts as a Salvage Procedure. <i>Cureus</i> , 2015, 7, e247.	0.2	4
193	Socioeconomic predictors of case presentations and outcomes in 225 nonfunctional pituitary adenoma resections. <i>Journal of Neurosurgery</i> , 2022, 136, 1325-1336.	0.9	4
194	Cerebrospinal Fluid Leaks and Pseudomeningocele after Posterior Fossa Surgery: Effect of an Autospray Dural Sealant. <i>Cureus</i> , 2020, 12, e8379.	0.2	4
195	Increased prevalence of obesity and obesity-related postoperative complications in male meningioma patients. <i>Clinical Neurosurgery</i> , 2007, 54, 236-40.	0.2	4
196	The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis. <i>Cancers</i> , 2019, 11, 1977.	1.7	3
197	Recent advancements in the molecular biology of pituitary adenomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 293-304.	1.2	3
198	The Endoscopic Buccal Fat Pad Flap for Closure of Skull Base Defects: A Report of 5 Cases. <i>World Neurosurgery</i> , 2018, 110, e42-e45.	0.7	2

#	ARTICLE	IF	CITATIONS
199	Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons. Journal of Neuro-Oncology, 2021, 151, 361-366.	1.4	2
200	Meningioma surgical outcomes and complications in patients aged 75 years and older. Journal of Clinical Neuroscience, 2021, 88, 88-94.	0.8	2
201	Effect of facility volume on giant pituitary adenoma neurosurgical outcomes. Journal of Neurosurgery, 2022, , 1-10.	0.9	2
202	Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy. World Neurosurgery, 2022, 162, e235-e245.	0.7	2
203	Interval, acute onset airway obstruction associated with a fracture of the C4 vertebra in a patient with ankylosing spondylitis. Journal of Clinical Neuroscience, 2010, 17, 1085-1088.	0.8	1
204	Headache and Focal Neurologic Deficits in a 37-Year-Old Woman. JAMA Neurology, 2013, 70, 1445.	4.5	1
205	Introduction to Pituitary Adenomas. Neurosurgery Clinics of North America, 2019, 30, xiii.	0.8	1
206	Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors. Journal of Neuro-Oncology, 2021, 151, 341-343.	1.4	1
207	Trends in physician reimbursements and procedural volumes for radiosurgery versus open surgery in brain tumor care: an analysis of Medicare data from 2009 to 2018. Journal of Neurosurgery, 2022, 136, 97-108.	0.9	1
208	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 63-75.	0.9	1
209	Antiangiogenic Therapy for Glioblastoma. , 2016, , 143-149.		1
210	Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget, 2019, 10, 4350-4350.	0.8	1
211	Preface. Neurosurgery Clinics of North America, 2012, 23, ix.	0.8	0
212	Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14024.	1.8	0
213	BMET-24CRANIOTOMY FOR TUMOR RESECTION IN PATIENTS WITH MULTIPLE BRAIN METASTASES: CHARACTERISTIC OF THE DOMINANT METASTATIC LESION. Neuro-Oncology, 2015, 17, v50.2-v50.	0.6	0
214	ACTR-33. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2016, 18, vi9-vi9.	0.6	0
215	TMOD-24. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY. Neuro-Oncology, 2016, 18, vi212-vi212.	0.6	0
216	Initial Experience with Intraoperative Phosphorous-32 Brachytherapy During Resection of Malignant Spinal Tumors. World Neurosurgery, 2018, 115, e785-e793.	0.7	0

#	ARTICLE	IF	CITATIONS
217	Endoscope Image Capture System with Mirrorless Camera. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 079-081.	0.4	0
218	Letter to the Editor Regarding "Global Diversity and Academic Success of Foreign-Trained Academic Neurosurgeons in the United States" World Neurosurgery, 2020, 139, 704-705.	0.7	0
219	In Reply to the Letter to the Editor "Regarding the Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017" World Neurosurgery, 2020, 143, 625.	0.7	0
220	In Reply to the Letter to the Editor Regarding "The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017" World Neurosurgery, 2020, 138, 594.	0.7	0
221	Can Private versus Government Insurance Predict Neurosurgical Outcomes? An Analysis of 218 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
222	Does Having a Primary Care Physician Predict Neurosurgical Outcomes? An Analysis of 225 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
223	OTME-12. Role of the transsulfuration pathway in glioblastoma invasion. Neuro-Oncology Advances, 2021, 3, ii15-ii16.	0.4	0
224	Presentation and management of post-operative cerebrospinal fluid leaks after sphenoclivar expanded endonasal surgery: A single institution experience. Journal of Clinical Neuroscience, 2021, 91, 13-19.	0.8	0
225	Pituitary Apoplexy. , 2017, , 499-516.		0
226	Atypical Pituitary Adenoma: A Clinicopathologic Case Series. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
227	Neuroendocrinological Outcomes Following Early versus Delayed Surgery for Acute Pituitary Apoplexy. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
228	Economic Burden and Cost-effectiveness of Endoscopic versus Microscopic Transsphenoidal Surgery for Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.4	0
229	Salvage surgery for local control of brain metastases after prior stereotactic radiosurgery: a single-center series. World Neurosurgery, 2021, , .	0.7	0
230	Lateral orientation of Rathke cleft cysts may be associated with high rates of recurrence after surgery. Pituitary, 0, , .	1.6	0